X4 Pharmaceuticals Restructures, Cuts Workforce by 50%, Saves $13M
ByAinvest
Wednesday, Sep 17, 2025 7:05 am ET1min read
XFOR--
X4 Pharmaceuticals announced a strategic restructuring, reducing its workforce by 50% to achieve annualized cost savings of approximately $13 million. The company also appointed John Volpone as Chief Operating Officer, in addition to his current role as President. Dr. Adam Craig will have oversight over clinical development. The restructuring is aimed at sharpening operational focus and aligning resources with the long-term strategy to complete the 4WARD Phase 3 trial in patients with chronic neutropenia.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet